Decitabine-Driven Foetal Haemoglobin Induction in Townes Mice and Human Erythroblasts.

ABSTRACT:

Background

Induction of foetal haemoglobin (HbF) is a clinically validated approach to modulate the severity of sickle cell disease (SCD). This manuscript evaluates the efficacy of decitabine, a DNA methyltransferase (DNMT) inhibitor, in inducing HbF in healthy human erythroblasts and Townes mice, which are well-established systems modelling SCD.

Methods

Healthy human erythroblasts were treated with decitabine, and HbF induction was measured. Townes sickle cell mice were administered decitabine for 12 weeks, and various haematological parameters were assessed.

Results

In healthy human erythroblasts, decitabine treatment resulted in a significant increase in the fraction of HbF-rich cells (F-cells), accompanied by elevated HbF protein levels. The HbF induction was supe

SUBMITTER: Carol Illa A 

PROVIDER: S-EPMC12320723 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature